New drug duo aims to supercharge immune attack on head and neck tumors before surgery

NCT ID NCT07455032

Recruiting now Disease control Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether adding an experimental drug (CADI-05) to standard immunotherapy (pembrolizumab) can help the immune system better fight advanced head and neck cancer before surgery. About 22 adults with resectable, locally advanced disease will receive both treatments for 5 weeks, then undergo surgery. Researchers will monitor side effects and check tumor response in removed tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

Contacts and locations

Locations

Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Temple University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19140, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.